CARsgen and Moderna to evaluate CT041 in combo with an mRNA cancer vaccine

22 August 2023

US mRNA specialist Moderna (Nasdaq: MRNA) saw its shares close up 9.3% at $111.08 on Monday after the announcement of a collaboration agreement to investigate Shanghai, China-based CARsgen Therapeutics’ (2171: HK) investigational Claudin18.2 CAR T-cell product candidate (CT041) in combination with Moderna’s investigational Claudin18.2 mRNA cancer vaccine.

CT041 (satricabtagene autoleucel), is CARsgen's autologous CAR T-cell product being investigated for the potential treatment of gastric, pancreatic, and other specified digestive system cancers and is currently in multiple ongoing clinical studies in China and North America.

Moderna is developing an investigational off-the-shelf mRNA cancer vaccine that encodes for the Claudin18.2 protein, a tumor associated antigen. The collaboration contemplates conducting pre-clinical studies and a Phase I clinical trial to evaluate CT041 in combination with Moderna’s Claudin18.2 mRNA cancer vaccine.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK